A Phase 1 interventional study of Etrolizumab in Ulcerative Colitis and Crohn's Disease, sponsored by Hoffmann-La Roche. Terminated at 5 sites in 4 countries. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-12-27.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing etrolizumab in Colitis, Ulcerative — none open to participants now, none under way, none of them phase 3. etrolizumab · Colitis, Ulcerative.
Among the 10 studies testing etrolizumab in Colitis, Ulcerative, this one is the 10th largest by enrollment, is the only one that started in 2018, is one of 2 in phase 1, and was the 10th registered.
1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →None of the 10 studies testing etrolizumab in Colitis, Ulcerative is open now. The open studies under Colitis, Ulcerative, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 4 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2018.
This study's enrollment of 24 is below the median of 70 across 1,238 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 358 across the 10 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 2 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
24 studies in Colitis, Ulcerative by Hoffmann-La Roche: 4 open now, 6 under way, 4 of them phase 3. Of 18 finished, 13 (72%) have results posted.
Among the 24 studies in Colitis, Ulcerative by Hoffmann-La Roche, this one is the 23rd largest by enrollment, is one of 2 that started in 2018, is one of 6 in phase 1, and was the 12th registered.
Hoffmann-La Roche’s Colitis, Ulcerative studies by the year they started, since 2008.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing etrolizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 24 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab in pediatric patients of 4 to \<18 years of age with moderate to severe ulcerative colitis (UC) or with moderate to severe Crohn's disease (CD).
Inclusion Criteria:
Exclusion Criteria:
Exclusion Criteria Related to Inflammatory Bowel Disease:
Exclusion Criteria Related to Ulcerative Colitis:
Exclusion Criteria Related to Crohn's Disease:
Exclusion Criteria Related to Prior or Concomitant Therapy:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Etrolizumab 1.5 milligrams per kilogram of body weight (mg/kg) was administered by subcutaneous (SC) injection once every 4 weeks (Q4W) for a total of 4 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
Drug: Etrolizumab
Etrolizumab 3.0 mg/kg was administered by subcutaneous (SC) injection once every 8 weeks (Q8W) for a total of 2 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
Drug: Etrolizumab
Etrolizumab was administered by subcutaneous (SC) injection as described for each treatment arm.
Also known as: RG7413, RO5490261, PRO145223, rhuMAb Beta7
Maximum Serum Concentration (Cmax) of Etrolizumab After First and Last Dose During the Randomized Treatment Phase
Etrolizumab concentrations in all pharmacokinetics (PK) samples were measured using a validated assay method. Non-compartmental analysis methods were employed to calculate PK parameters.
Time frame: Arm Etro Q4W: Day 1, 84 and Arm Etro Q8W: Day 1, 56
Time to Maximum Serum Concentration (Tmax) of Etrolizumab After First and Last Dose During the Randomized Treatment Phase
Etrolizumab concentrations in all pharmacokinetics (PK) samples were measured using a validated assay method. Non-compartmental analysis methods were employed to calculate PK parameters.
Time frame: Arm Etro Q4W: Days 1, 84 and Arm Etro Q8W: Days 1, 56
Area Under the Concentration-Time Curve Within the Last Dosing Interval (AUC-tau) of Etrolizumab During the Randomized Treatment Phase
Etrolizumab concentrations in all pharmacokinetics (PK) samples were measured using a validated assay method. Non-compartmental analysis methods were employed to calculate PK parameters.
Time frame: Arm Etro Q4W: Days 56, 84, 88, 98, 112 and Arm Etro Q8W: Day 56, 60, 70, 84, 88, 98, 112
Elimination Half-Life (t1/2) of Etrolizumab After Last Dose During the Randomized Treatment Phase
Etrolizumab concentrations in all pharmacokinetics (PK) samples were measured using a validated assay method. Non-compartmental analysis methods were employed to calculate PK parameters.
Time frame: Arm Etro Q4W: Days 84, 88, 98, 112, 126, 140, 168 and Arm Etro Q8W: Days 56, 60, 70, 84, 88, 98, 112, 126, 140, 168
Serum Trough Concentration (Ctrough) of Etrolizumab at the End of Each Dosing Interval During the Randomized Treatment Phase
Etrolizumab concentrations in all pharmacokinetics (PK) samples were measured using a validated assay method.
Time frame: Arm Etro Q4W: Predose on Days 28, 56, 84, 112 and Arm Etro Q8W: Predose on Days 56, 112
Percentage of Baseline Absolute Numbers of Beta7 Receptor-Expressing Gut Homing CD3, CD4, and CD8 T Cells and CD19 B Cells With Unoccupied Beta7 Receptors in Peripheral Blood, Assessed by Flow Cytometry, During the Randomized Treatment Phase
Target engagement of etrolizumab was assessed via measurement of Beta7 receptor occupancy on Beta7 receptor-expressing gut homing lymphocyte subsets in peripheral blood, including CD3, CD4, and CD8 T cells and CD19 B cells, using qualified flow cytometry methods. A decrease to 0% of baseline (BL) in median absolute cell counts of Beta7 receptor-expressing T and B cell subsets with unoccupied Beta7 receptors following etrolizumab treatment indicated maximal receptor occupancy by etrolizumab.
Time frame: Predose (dosing days only) at Baseline (Day 1) and on Days 4, 56, 84, 98, and 112 (Treatment Period), and Days 126, 140, and 168 (Follow-Up Period)
Number of Participants With Adverse Events by Highest Severity Grade, Assessed According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0), During the Randomized Treatment Phase
All adverse events (AEs) were graded for severity using the NCI-CTCAE v4.0. Any AE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to AE. Not all grades are appropriate for all AEs; some AEs have fewer than 5 options. The terms "severe" and "serious" are not synonymous and are independently assessed for each AE. Multiple occurrences of AEs were counted only once per participant at the highest (worst) grade.
Time frame: From Baseline until 12 weeks (Q4W arm only) or 16 weeks (Q8W arm only) after the last dose of study drug during the randomized treatment phase (up to 24 weeks)
Number of Participants With Serious Infection-Related Adverse Events During the Randomized Treatment Phase
Serious infection-related AEs were assessed using NCI-CTCAE v4.0.
Time frame: From Baseline until 12 weeks (Q4W arm only) or 16 weeks (Q8W arm only) after the last dose of study drug during the randomized treatment phase (up to 24 weeks)
Number of Participants With Hypersensitivity Reactions During the Randomized Treatment Phase
Hypersensitivity reactions were assessed using NCI-CTCAE v4.0.
Time frame: From Baseline until 12 weeks (Q4W arm only) or 16 weeks (Q8W arm only) after the last dose of study drug during the randomized treatment phase (up to 24 weeks)
Number of Participants With Malignancies During the Randomized Treatment Phase
Malignancies were assessed using NCI-CTCAE v4.0.
Time frame: From Baseline until 12 weeks (Q4W arm only) or 16 weeks (Q8W arm only) after the last dose of study drug during the randomized treatment phase (up to 24 weeks)
Number of Participants With Anti-Drug Antibodies (ADAs) to Etrolizumab at Baseline and Post-Baseline During the Randomized Treatment Phase
Participants were considered to be etrolizumab anti-drug antibody (ADA) positive if they were ADA negative or had missing data at Baseline (BL) but developed an ADA response following study drug exposure (i.e., treatment-induced ADA positive), or if they were ADA positive at baseline and the titer of one or more postbaseline samples was at least 0.60 titer unit greater than the titer of the baseline sample (i.e., treatment-enhanced ADA positive); these ADA positive responses are summarized together (induced + enhanced) in the 'treatment-emergent ADA positive' category. Participants were considered to be ADA negative if they were ADA negative or had missing data at Baseline (BL) and all postbaseline samples were negative (i.e., treatment-emergent ADA negative).
Time frame: Predose (dosing days only) on Days 1, 28, 84, 112, and 168 (up to the end of the randomized treatment phase at Week 24)
Long-Term Safety of Etrolizumab: Number of Participants With Adverse Events by Highest Severity Grade, Assessed According to NCI-CTCAE v4.0
All adverse events (AEs) were graded for severity using the NCI-CTCAE v4.0. Any AE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to AE. Not all grades are appropriate for all AEs; some AEs have fewer than 5 options. The terms "severe" and "serious" are not synonymous and are independently assessed for each AE. Multiple occurrences of AEs were counted only once per participant at the highest (worst) grade.
Time frame: OLE Period: From end of Week 24 to end of 12-week safety follow-up (up to 195 weeks); PML Period: After completion of safety follow up in Randomized Treatment phase or after completion of safety follow up after OLE treatment, up to approximately 92 weeks
Long-Term Safety of Etrolizumab: Number of Participants With Serious Infection-Related Adverse Events
Serious infection-related AEs were assessed using NCI-CTCAE v4.0.
Time frame: OLE Period: From end of Week 24 to end of 12-week safety follow-up (up to 195 weeks); PML Period: After completion of safety follow up in Randomized Treatment phase or after completion of safety follow up after OLE treatment, up to approximately 92 weeks
Long-Term Safety of Etrolizumab: Number of Participants With Hypersensitivity Reactions
Hypersensitivity reactions were assessed using NCI-CTCAE v4.0.
Time frame: OLE Period: From end of Week 24 to end of 12-week safety follow-up (up to 195 weeks); PML Period: After completion of safety follow up in Randomized Treatment phase or after completion of safety follow up after OLE treatment, up to approximately 92 weeks
Long-Term Safety of Etrolizumab: Number of Participants With Malignancies
Malignancies were assessed using NCI-CTCAE v4.0.
Time frame: OLE Period: From end of Week 24 to end of 12-week safety follow-up (up to 195 weeks); PML Period: After completion of safety follow up in Randomized Treatment phase or after completion of safety follow up after OLE treatment, up to approximately 92 weeks
Long-Term Safety of Etrolizumab: Number of Participants With Anti-Drug Antibodies (ADAs) to Etrolizumab at Baseline and Post-Baseline
Participants were considered to be etrolizumab anti-drug antibody (ADA) positive if they were ADA negative or had missing data at Baseline (BL) but developed an ADA response following study drug exposure (i.e., treatment-induced ADA positive), or if they were ADA positive at baseline and the titer of one or more postbaseline samples was at least 0.60 titer unit greater than the titer of the baseline sample (i.e., treatment-enhanced ADA positive); these ADA positive responses are summarized together (induced + enhanced) in the 'treatment-emergent ADA positive' category. Participants were considered to be ADA negative if they were ADA negative or had missing data at Baseline (BL) and all postbaseline samples were negative (i.e., treatment-emergent ADA negative).
Time frame: Predose (dosing days only) at Baseline (Day 1), Days 28, 84, and 112, Weeks 24, 36, 72, and 120, and every 12 weeks thereafter for up to 4.25 years
Number of Participants With Confirmed Progressive Multifocal Leukoencephalopathy (PML) During the Post-Treatment PML Monitoring Phase
The safety surveillance PML-monitoring phase (no etrolizumab treatment) consisted of telephone calls approximately every 6 months with administration of the protocol's PML Subjective Checklist. If there were any signs or symptoms suggestive of PML identified on this subjective checklist during the telephone call, the participant was asked to come into the clinic for a neurologic examination. The protocol's PML Algorithm was followed for any suspected case of PML, and any confirmed case of PML would be reported as a serious adverse event.
Time frame: PML Period: After completion of safety follow up in Randomized Treatment period or after completion of safety follow up after OLE treatment, up to approximately 92 weeks
| Milestone | Etrolizumab Q4W | Etrolizumab Q8W | OLE: Etrolizumab 1.5 mg Q4W | PML Safety Monitoring |
|---|---|---|---|---|
| Started | 12 | 12 | 0 | 0 |
| Received at least one dose of study drug | 12 | 12 | 0 | 0 |
| Completed treatment | 11 | 10 | 0 | 0 |
| Completed | 11 | 11 | 0 | 0 |
| Not completed | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Milestone | Etrolizumab Q4W | Etrolizumab Q8W | OLE: Etrolizumab 1.5 mg Q4W | PML Safety Monitoring |
|---|---|---|---|---|
| Started | 0 | 0 | 21 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 21 | 0 |
| Withdrew: Adverse event | 0 | 0 | 4 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 8 | 0 |
| Withdrew: Reason not provided | 0 | 0 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 6 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 0 |
| Milestone | Etrolizumab Q4W | Etrolizumab Q8W | OLE: Etrolizumab 1.5 mg Q4W | PML Safety Monitoring |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 13 |
| Completed | 0 | 0 | 0 | 4 |
| Not completed | 0 | 0 | 0 | 9 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 9 |
Etrolizumab concentrations in all pharmacokinetics (PK) samples were measured using a validated assay method. Non-compartmental analysis methods were employed to calculate PK parameters.
| micrograms per millilitre (μg/mL) | Etrolizumab Q4W | Etrolizumab Q8W |
|---|---|---|
| After First Dose (Day 1) | 7.73 ± 2.18 | 19.0 ± 8.21 |
| After Last Dose (Q4W Day 84, Q8WDay 56) | 9.80 ± 4.86 | 18.1 ± 6.25 |
Etrolizumab concentrations in all pharmacokinetics (PK) samples were measured using a validated assay method. Non-compartmental analysis methods were employed to calculate PK parameters.
| Day | Etrolizumab Q4W | Etrolizumab Q8W |
|---|---|---|
| After First Dose (Day 1) | 4.65 ± 1.43 | 4.00 ± 1.48 |
| After Last Dose (Q4W Day 84, Q8WDay 56) | 5.04 ± 2.92 | 4.94 ± 3.28 |
Etrolizumab concentrations in all pharmacokinetics (PK) samples were measured using a validated assay method. Non-compartmental analysis methods were employed to calculate PK parameters.
| Day*μg/mL | Etrolizumab Q4W | Etrolizumab Q8W |
|---|---|---|
| AUC56-112 | — | 521 ± 306 |
| AUC84-112 | 167 ± 86.9 | — |
Etrolizumab concentrations in all pharmacokinetics (PK) samples were measured using a validated assay method. Non-compartmental analysis methods were employed to calculate PK parameters.
| Day | Etrolizumab Q4W | Etrolizumab Q8W |
|---|---|---|
| Elimination Half-Life (t1/2) of Etrolizumab After Last Dose During the Randomized Treatment Phase | 7.31 ± 1.76 | 8.65 ± 3.74 |
Etrolizumab concentrations in all pharmacokinetics (PK) samples were measured using a validated assay method.
| micrograms per millilitre (μg/mL) | Etrolizumab Q4W | Etrolizumab Q8W |
|---|---|---|
| Day 28 | 1.87 ± 1.32 | — |
| Day 56 | 3.22 ± 2.24 | 1.82 ± 1.99 |
| Day 84 | 3.00 ± 2.38 | — |
| Day 112 | 2.79 ± 2.01 | 3.70 ± 4.64 |
Target engagement of etrolizumab was assessed via measurement of Beta7 receptor occupancy on Beta7 receptor-expressing gut homing lymphocyte subsets in peripheral blood, including CD3, CD4, and CD8 T cells and CD19 B cells, using qualified flow cytometry methods. A decrease to 0% of baseline (BL) in median absolute cell counts of Beta7 receptor-expressing T and B cell subsets with unoccupied Beta7 receptors following etrolizumab treatment indicated maximal receptor occupancy by etrolizumab.
| Percentage of BL Unoccupied Beta7 Cells | Etrolizumab Q4W | Etrolizumab Q8W |
|---|---|---|
| CD3 T Cells: Baseline | 100 ± 0.0 | 100 ± 0.0 |
| CD3 T Cells: Day 4 | 0.18 ± 0.2 | 0.40 ± 0.4 |
| CD3 T Cells: Day 56 | 1.92 ± 1.9 | 13.74 ± 13.5 |
| CD3 T Cells: Day 84 | 7.43 ± 6.0 | 1.06 ± 1.1 |
| CD3 T Cells: Day 98 | 0.36 ± 0.4 | 1.06 ± 1.1 |
| CD3 T Cells: Day 112 | 4.06 ± 2.6 | 6.01 ± 5.6 |
| CD3 T Cells: Day 126 | 12.00 ± 12.0 | 27.24 ± 24.6 |
| CD3 T Cells: Day 140 | 47.47 ± 21.9 | 56.82 ± 22.2 |
| CD3 T Cells: Day 168 | 71.64 ± 22.4 | 51.79 ± 23.1 |
| CD4 T Cells: Baseline | 100 ± 0.0 | 100 ± 0.0 |
| CD4 T Cells: Day 4 | 0.17 ± 0.2 | 0.00 ± 0.0 |
| CD4 T Cells: Day 56 | 3.33 ± 3.3 | 16.56 ± 16.1 |
| CD4 T Cells: Day 84 | 7.14 ± 7.1 | 1.28 ± 1.0 |
| CD4 T Cells: Day 98 | 0.24 ± 0.2 | 1.28 ± 1.3 |
| CD4 T Cells: Day 112 | 3.60 ± 3.1 | 6.74 ± 6.4 |
| CD4 T Cells: Day 126 | 13.33 ± 13.3 | 37.03 ± 33.7 |
| CD4 T Cells: Day 140 | 55.34 ± 23.9 | 62.01 ± 20.3 |
| CD4 T Cells: Day 168 | 74.49 ± 26.1 | 50.00 ± 16.3 |
| CD8 T Cells: Baseline | 100 ± 0.0 | 100 ± 0.0 |
| CD8 T Cells: Day 4 | 0.00 ± 0.0 | 0.00 ± 0.0 |
| CD8 T Cells: Day 56 | 1.56 ± 1.6 | 8.41 ± 8.4 |
| CD8 T Cells: Day 84 | 2.72 ± 2.7 | 0.00 ± 0.0 |
| CD8 T Cells: Day 98 | 1.10 ± 1.1 | 2.33 ± 2.3 |
| CD8 T Cells: Day 112 | 0.97 ± 1.0 | 2.46 ± 2.5 |
| CD8 T Cells: Day 126 | 20.00 ± 20.0 | 14.51 ± 14.5 |
| CD8 T Cells: Day 140 | 54.17 ± 18.8 | 40.98 ± 24.7 |
| CD8 T Cells: Day 168 | 63.34 ± 40.1 | 55.56 ± 21.1 |
| CD19 B Cells: Baseline | 100 ± 0.0 | 100 ± 0.0 |
| CD19 B Cells: Day 4 | 0.00 ± 0.0 | 0.00 ± 0.0 |
| CD19 B Cells: Day 56 | 3.57 ± 3.6 | 19.14 ± 17.1 |
| CD19 B Cells: Day 84 | 10.71 ± 10.7 | 0.00 ± 0.0 |
| CD19 B Cells: Day 98 | 0.00 ± 0.0 | 0.00 ± 0.0 |
| CD19 B Cells: Day 112 | 7.14 ± 7.1 | 7.14 ± 7.1 |
| CD19 B Cells: Day 126 | 42.86 ± 21.4 | 33.93 ± 32.3 |
| CD19 B Cells: Day 140 | 68.00 ± 30.5 | 77.78 ± 32.6 |
| CD19 B Cells: Day 168 | 73.21 ± 17.7 | 40.00 ± 13.2 |
All adverse events (AEs) were graded for severity using the NCI-CTCAE v4.0. Any AE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to AE. Not all grades are appropriate for all AEs; some AEs have fewer than 5 options. The terms "severe" and "serious" are not synonymous and are independently assessed for each AE. Multiple occurrences of AEs were counted only once per participant at the highest (worst) grade.
| Participants | Etrolizumab Q4W | Etrolizumab Q8W |
|---|---|---|
| Any Adverse Event - Any Grade | 9 | 10 |
| Any Adverse Event - Grade 1 | 2 | 2 |
| Any Adverse Event - Grade 2 | 4 | 5 |
| Any Adverse Event - Grade 3 | 3 | 3 |
| Any Adverse Event - Grade 4 | 0 | 0 |
| Any Adverse Event - Grade 5 | 0 | 0 |
Serious infection-related AEs were assessed using NCI-CTCAE v4.0.
| Participants | Etrolizumab Q4W | Etrolizumab Q8W |
|---|---|---|
| Number of Participants With Serious Infection-Related Adverse Events During the Randomized Treatment Phase | 0 | 0 |
Hypersensitivity reactions were assessed using NCI-CTCAE v4.0.
| Participants | Etrolizumab Q4W | Etrolizumab Q8W |
|---|---|---|
| Number of Participants With Hypersensitivity Reactions During the Randomized Treatment Phase | 0 | 0 |
Malignancies were assessed using NCI-CTCAE v4.0.
| Participants | Etrolizumab Q4W | Etrolizumab Q8W |
|---|---|---|
| Number of Participants With Malignancies During the Randomized Treatment Phase | 0 | 0 |
Participants were considered to be etrolizumab anti-drug antibody (ADA) positive if they were ADA negative or had missing data at Baseline (BL) but developed an ADA response following study drug exposure (i.e., treatment-induced ADA positive), or if they were ADA positive at baseline and the titer of one or more postbaseline samples was at least 0.60 titer unit greater than the titer of the baseline sample (i.e., treatment-enhanced ADA positive); these ADA positive responses are summarized together (induced + enhanced) in the 'treatment-emergent ADA positive' category. Participants were considered to be ADA negative if they were ADA negative or had missing data at Baseline (BL) and all postbaseline samples were negative (i.e., treatment-emergent ADA negative).
| Participants | Etrolizumab Q4W | Etrolizumab Q8W |
|---|---|---|
| Baseline (BL): ADA Positive | 1 | 0 |
| BL: ADA Negative | 11 | 12 |
| Post-BL: Treatment-Emergent ADA Positive | 4 | 2 |
| Post-BL: Treatment-Emergent ADA Negative | 7 | 10 |
All adverse events (AEs) were graded for severity using the NCI-CTCAE v4.0. Any AE not specifically listed was assessed per the following 5 grades: Grade 1 = mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; or intervention not indicated. Grade 2 = moderate; minimal, local, or non-invasive intervention indicated; or limiting age-appropriate instrumental activities of daily living. Grade 3 = severe or medically significant, but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care activities of daily living. Grade 4 = life-threatening consequences or urgent intervention indicated. Grade 5 = death related to AE. Not all grades are appropriate for all AEs; some AEs have fewer than 5 options. The terms "severe" and "serious" are not synonymous and are independently assessed for each AE. Multiple occurrences of AEs were counted only once per participant at the highest (worst) grade.
| Participants | OLE: Etrolizumab 1.5 mg Q4W | PML Safety Monitoring |
|---|---|---|
| Any Adverse Event - Any Grade | 20 | 4 |
| Any Adverse Event - Grade 1 | 0 | 2 |
| Any Adverse Event - Grade 2 | 12 | 2 |
| Any Adverse Event - Grade 3 | 8 | 0 |
| Any Adverse Event - Grade 4 | 0 | 0 |
| Any Adverse Event - Grade 5 | 0 | 0 |
Serious infection-related AEs were assessed using NCI-CTCAE v4.0.
| Participants | OLE: Etrolizumab 1.5 mg Q4W | PML Safety Monitoring |
|---|---|---|
| Long-Term Safety of Etrolizumab: Number of Participants With Serious Infection-Related Adverse Events | 1 | 0 |
Hypersensitivity reactions were assessed using NCI-CTCAE v4.0.
| Participants | OLE: Etrolizumab 1.5 mg Q4W | PML Safety Monitoring |
|---|---|---|
| Long-Term Safety of Etrolizumab: Number of Participants With Hypersensitivity Reactions | 4 | 1 |
Malignancies were assessed using NCI-CTCAE v4.0.
| Participants | OLE: Etrolizumab 1.5 mg Q4W | PML Safety Monitoring |
|---|---|---|
| Long-Term Safety of Etrolizumab: Number of Participants With Malignancies | 0 | 0 |
Participants were considered to be etrolizumab anti-drug antibody (ADA) positive if they were ADA negative or had missing data at Baseline (BL) but developed an ADA response following study drug exposure (i.e., treatment-induced ADA positive), or if they were ADA positive at baseline and the titer of one or more postbaseline samples was at least 0.60 titer unit greater than the titer of the baseline sample (i.e., treatment-enhanced ADA positive); these ADA positive responses are summarized together (induced + enhanced) in the 'treatment-emergent ADA positive' category. Participants were considered to be ADA negative if they were ADA negative or had missing data at Baseline (BL) and all postbaseline samples were negative (i.e., treatment-emergent ADA negative).
| Participants | Etrolizumab Q4W | Etrolizumab Q8W |
|---|---|---|
| Baseline (BL): ADA Positive | 1 | 0 |
| BL: ADA Negative | 11 | 12 |
| Post-BL: Treatment-Emergent ADA Positive | 4 | 3 |
| Post-BL: Treatment-Emergent ADA Negative | 7 | 9 |
The safety surveillance PML-monitoring phase (no etrolizumab treatment) consisted of telephone calls approximately every 6 months with administration of the protocol's PML Subjective Checklist. If there were any signs or symptoms suggestive of PML identified on this subjective checklist during the telephone call, the participant was asked to come into the clinic for a neurologic examination. The protocol's PML Algorithm was followed for any suspected case of PML, and any confirmed case of PML would be reported as a serious adverse event.
| Participants | PML Safety Monitoring |
|---|---|
| Number of Participants With Confirmed Progressive Multifocal Leukoencephalopathy (PML) During the Post-Treatment PML Monitoring Phase | 0 |
Collected over From Baseline up to the last dose of drug in the Randomized Treatment phase (up to 24 weeks); OLE Period: From end of Week 24 up to end of 12-week safety follow-up (up to 195 weeks); PML Period: After completion of safety follow up in the Randomized Treatment phase or after completion of safety follow up after OLE treatment, up to approximately 92 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Etrolizumab Q4W | 0/12 (0%) | 2/12 (16.7%) | 8/12 (66.7%) |
| Etrolizumab Q8W | 0/12 (0%) | 2/12 (16.7%) | 9/12 (75%) |
| OLE: Etrolizumab 1.5 mg/kg Q4W | 0/21 (0%) | 6/21 (28.6%) | 20/21 (95.2%) |
| PML Safety Monitoring | 0/13 (0%) | 0/13 (0%) | 4/13 (30.8%) |
| Event | Etrolizumab Q4W | Etrolizumab Q8W | OLE: Etrolizumab 1.5 mg/kg Q4W | PML Safety Monitoring |
|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 0/12 | 1/12 | 2/21 | 0/13 |
| Crohn's diseaseGastrointestinal disorders | 0/12 | 1/12 | 2/21 | 0/13 |
| AnaemiaBlood and lymphatic system disorders | 1/12 | 0/12 | 0/21 | 0/13 |
| DiarrhoeaGastrointestinal disorders | 1/12 | 0/12 | 0/21 | 0/13 |
| GastritisGastrointestinal disorders | 1/12 | 0/12 | 0/21 | 0/13 |
| VomitingGastrointestinal disorders | 1/12 | 0/12 | 0/21 | 0/13 |
| Anxiety disorderPsychiatric disorders | 1/12 | 0/12 | 0/21 | 0/13 |
| SinusitisInfections and infestations | 0/12 | 0/12 | 1/21 | 0/13 |
| Idiopathic intracranial hypertensionNervous system disorders | 0/12 | 0/12 | 1/21 | 0/13 |
| Drug abusePsychiatric disorders | 0/12 | 0/12 | 1/21 | 0/13 |
| Event | Etrolizumab Q4W | Etrolizumab Q8W | OLE: Etrolizumab 1.5 mg/kg Q4W | PML Safety Monitoring |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 2/12 | 0/12 | 8/21 | 0/13 |
| Colitis ulcerativeGastrointestinal disorders | 2/12 | 0/12 | 7/21 | 0/13 |
| PyrexiaGeneral disorders | 4/12 | 0/12 | 6/21 | 1/13 |
| Abdominal painGastrointestinal disorders | 3/12 | 2/12 | 6/21 | 0/13 |
| AnaemiaBlood and lymphatic system disorders | 3/12 | 1/12 | 4/21 | 0/13 |
| HeadacheNervous system disorders | 0/12 | 3/12 | 5/21 | 0/13 |
| Crohn's diseaseGastrointestinal disorders | 2/12 | 2/12 | 5/21 | 0/13 |
| PharyngitisInfections and infestations | 0/12 | 0/12 | 5/21 | 0/13 |
| Abdominal pain upperGastrointestinal disorders | 1/12 | 0/12 | 4/21 | 2/13 |
| Respiratory tract infectionInfections and infestations | 1/12 | 0/12 | 4/21 | 0/13 |
| Age, Continuous(Years) | Etrolizumab Q4W | Etrolizumab Q8W | Total |
|---|---|---|---|
| Mean | 12.25 ± 3.62 | 13.42 ± 4.46 | 12.83 ± 4.02 |
| Sex: Female, Male(Participants) | Etrolizumab Q4W | Etrolizumab Q8W | Total |
|---|---|---|---|
| Female | 4 | 7 | 11 |
| Male | 8 | 5 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Etrolizumab Q4W | Etrolizumab Q8W | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 12 | 11 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Etrolizumab Q4W | Etrolizumab Q8W | Total |
|---|---|---|---|
| White | 12 | 12 | 24 |
| Disease Indication: Crohn's Disease or Ulcerative Colitis(Participants) | Etrolizumab Q4W | Etrolizumab Q8W | Total |
|---|---|---|---|
| Crohn's Disease | 5 | 5 | 10 |
| Ulcerative Colitis | 7 | 7 | 14 |
| Randomization Stratification Factor: Body Weight <40 kg or ≥40 kg(Participants) | Etrolizumab Q4W | Etrolizumab Q8W | Total |
|---|---|---|---|
| <40 kg | 5 | 4 | 9 |
| ≥40 kg | 7 | 8 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Dec 2019, 20 months.
Results were first posted in Aug 2020, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etrolizumab